Oncogenic hijacking of a developmental transcription factor evokes vulnerability toward oxidative stress in Ewing sarcoma by Marchetto, A. et al.
ARTICLE
Oncogenic hijacking of a developmental
transcription factor evokes vulnerability toward
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Ewing sarcoma (EwS) is an aggressive childhood cancer likely originating from mesenchymal
stem cells or osteo-chondrogenic progenitors. It is characterized by fusion oncoproteins
involving EWSR1 and variable members of the ETS-family of transcription factors (in 85%
FLI1). EWSR1-FLI1 can induce target genes by using GGAA-microsatellites as enhancers.
Here, we show that EWSR1-FLI1 hijacks the developmental transcription factor SOX6 – a
physiological driver of proliferation of osteo-chondrogenic progenitors – by binding to an
intronic GGAA-microsatellite, which promotes EwS growth in vitro and in vivo. Through
integration of transcriptome-profiling, published drug-screening data, and functional in vitro
and in vivo experiments including 3D and PDX models, we discover that constitutively high
SOX6 expression promotes elevated levels of oxidative stress that create a therapeutic
vulnerability toward the oxidative stress-inducing drug Elesclomol.
Collectively, our results exemplify how aberrant activation of a developmental transcription
factor by a dominant oncogene can promote malignancy, but provide opportunities for tar-
geted therapy.
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Ewing sarcoma (EwS) is the second most common bone orsoft-tissue cancer in children and adolescents1. Even thoughthe cell of origin of EwS is still debated, increasing evidence
suggests that it may arise from mesenchymal stem cell (MSC)-
derived early committed osteo-chondrogenic progenitors2,3.
Indeed, EwS cells display a highly undifferentiated and embryonal
phenotype. Clinically, EwS is a rapidly metastasizing cancer, and
~25% of cases are metastatic at initial diagnosis1. While great
advances in treatment of localized disease have been achieved,
established therapies still have limited success in advanced stages
despite high toxicity1. Thus, more specific and in particular less
toxic therapies are urgently required.
As a genetic hallmark, EwS tumors express chimeric EWSR1-
ETS (EwS breakpoint region 1—E26 transformation specific)
fusion oncoproteins generated through fusion of the EWSR1 gene
and variable members of the ETS-family of transcription factors,
most commonly FLI1 (85% of all cases)4,5. Prior studies
demonstrated that EWSR1-FLI1 acts as a pioneer transcription
factor that massively rewires the tumor transcriptome ultimately
promoting the malignant phenotype of EwS6,7. This is in part
mediated through interference with and/or aberrant activation of
developmental pathways3,8. Remarkably, EWSR1-FLI1 regulates
~40% of its target genes by binding to otherwise non-functional
GGAA-microsatellites (mSats)9 that are thereby converted into
potent de novo enhancers, whose activity increases with the
number of consecutive GGAA-repeats7,10–12.
Although EWSR1-FLI1 would in principle constitute a highly
specific target for therapy, this fusion oncoprotein proved to be
notoriously difficult to target due to its intranuclear localization,
its activity as a transcription factor13,14, the absence of regulatory
protein residues1, its low immunogenicity15, and the high and
ubiquitous expression of its constituting genes in adult tissues1.
Hence, we reasoned that developmental genes and pathways that
are aberrantly activated by EWSR1-FLI1 and virtually inactive in
normal adult tissues, could constitute druggable surrogate targets.
As EwS most commonly arises in bone and possibly descends
from osteo-chondrogenic progenitor cells3, we speculated that
EWSR1-FLI1 might interfere with bone developmental pathways.
The transcription and splicing factor SOX6 (SRY-box 6) plays an
important role in endochondral ossification16. Interestingly, its
transient high expression delineates cells along the osteo-
chondrogenic lineage showing high rates of proliferation while
maintaining an immature phenotype along this lineage17–19.
In the current study, we show that EWSR1-FLI1 binds to an
intronic GGAA-mSat within SOX6, which acts as an EWSR1-
FLI1-dependent enhancer that induces the high and constitutive
overexpression of SOX6 in EwS tumors. Moreover, we report that
SOX6 promotes proliferation and tumorigenicity of EwS cells, and
confers a druggable therapeutic vulnerability toward the oxidative
stress-inducing small-molecule Elesclomol, through upregulation
of cell intrinsic oxidative stress starting from mitochondria.
Results
SOX6 is highly but variably expressed in EwS. To explore the
expression pattern of SOX6, we took advantage of a well-curated
set of >750 DNA microarrays20, comprising 18 representative
normal tissues types and 10 cancer entities. Comparative analyses
revealed that SOX6 is overexpressed in EwS relative to normal
tissues and other cancers (Fig. 1a). These data were validated at
the protein level in a comprehensive tissue microarray20, com-
prising the same normal tissue types and cancer entities (Fig. 1b,
c). Both analyses showed that SOX6 is highly expressed in EwS
tumors, albeit with substantial inter-tumor heterogeneity.
The generally high but variable expression of SOX6 was also
observed in EwS cell line models compared to cell lines of three
other pediatric cancer types including osteosarcoma (U2OS and
SAOS-2), neuroblastoma (TGW and SK-N-AS) and rhabdomyo-
sarcoma (Rh36 and Rh4) (Supplementary Fig. 1).
EWSR1-FLI1 induces SOX6 expression via an intronic
GGAA-mSat. The relatively high expression of SOX6 in EwS
compared to other sarcomas and pediatric cancers implied that
there might be a regulatory relationship with the EwS specific
fusion oncogene EWSR1-FLI1. Indeed, knockdown of EWSR1-
FLI1 in A673/TR/shEF1 and SK-N-MC/TR/shEF1 cells harboring
a doxycycline (Dox)-inducible short hairpin RNA (shRNA)
against the fusion gene, strongly reduced SOX6 expression in a
time-dependent manner in vitro (Fig. 2a, Supplementary Fig. 2a)
and in vivo (Fig. 2b). Conversely, ectopic expression of EWSR1-
FLI1 in human embryoid bodies strongly induced SOX6 expres-
sion (Fig. 2c).
To investigate the underlying mechanism of this regulatory
relationship, we analyzed publicly available DNase-Seq and ChIP-
Seq data of two EwS cell lines (A673 and SK-N-MC) and found a
prominent EWSR1-FLI1 peak within intron 1 of SOX6, which
was strongly reduced upon EWSR1-FLI1 knockdown (Fig. 2d).
This EWSR1-FLI1 peak mapped to a GGAA-mSat located within
a DNase 1 hypersensitivity site, indicating open chromatin, and
showed EWSR1-FLI1-dependent acetylation of H3K27, which
marks active enhancers (Fig. 2d). The EWSR1-FLI1-dependent
enhancer activity of this GGAA-mSat was confirmed by luciferase
reporter assays in A673/TR/shEF1 cells transfected with pGL3
reporter plasmids in which we cloned a 1-kb fragment containing
this SOX6-associated GGAA-mSat from the human reference
genome (Fig. 2e).
As prior studies showed that the enhancer activity at EWSR1-
FLI1-bound GGAA-mSats positively correlates with the number
of consecutive GGAA-repeats10,21,22, we hypothesized that the
observed variability in SOX6 expression might be caused by
differences in repeat numbers at the SOX6-associated GGAA-
mSat. To test this possibility, we cloned both alleles of this mSat
from eight EwS cell lines with largely different SOX6 expression
levels (Supplementary Fig. 1), determined their repeat number by
Sanger sequencing, and measured their enhancer activity in
reporter assays. We observed a statistically significant (P= 0.016)
positive correlation of the average SOX6 expression levels with
the relative average enhancer activity across cell lines, which
corresponded to the average repeat numbers of both alleles
(Fig. 2f, Supplementary Table 1). Interestingly, the inter-
individual differences in SOX6 expression levels correlated
neither with (minor) differences of SOX6 promoter methylation
nor with copy number variations at the SOX6 locus in primary
EwS tumors (Supplementary Fig. 2b, c).
Collectively, these data suggest that EWSR1-FLI1 induces
SOX6 by binding to a polymorphic intronic GGAA-mSat, which
exhibits length-dependent enhancer activity.
SOX6 promotes proliferation of EwS in vitro and in vivo. To
investigate the possible function of SOX6 in EwS, we generated
two cell lines (RDES and TC-32) with Dox-inducible shRNAs
against SOX6 (shSOX6_2 and shSOX6_3) and corresponding
controls with a Dox-inducible non-targeting control shRNA
(shCtrl). In these transduced cells, addition of Dox (0.1 µg/ml) to
the culture medium effectively silenced SOX6 expression at the
mRNA and protein level (Fig. 3a, Supplementary Fig. 3a).
Since SOX6 acts—depending on the cellular context—as a
splicing and/or transcription factor23,24, we examined the effect of
SOX6 knockdown in RDES and TC-32 EwS cell lines using
Affymetrix Clariom D arrays, which enable the simultaneous
transcriptome-wide analysis of splicing events and differential
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gene expression. While the knockdown of SOX6 for 96 h had little
effect on splicing (Supplementary Data 1), we noted a strong
effect on differential gene expression (Fig. 3b). In fact, SOX6
silencing induced a concordant up- or downregulation (min.
absolute log2 FC of 1) of 54 and 499 genes, respectively, across
shRNAs and cell lines (Supplementary Data 2). Gene set
enrichment analysis (GSEA) of the entire set of differentially
expressed genes (DEGs) identified a strong depletion of
proliferation-related gene signatures in SOX6-silenced EwS cells
(Fig. 3b, Supplementary Data 3).
To validate the predicted role of SOX6 in EwS proliferation, we
performed knockdown experiments using pooled short interfer-
ing RNAs (sipool) against SOX6 in five EwS cell lines (A673,
EW7, POE, RDES, and TC-32). Each sipool consisted of 30
different siRNAs, which virtually eliminates off-target effects25,
and which induced a 60–80% SOX6 knockdown as compared to a
a
c
b800
ASPS
Nephro-
blastoma
Adrenal
gland Gallbladder
Bone marrow
Endometrium
Esophagus
Fat Lung Skin
Liver Prostate
Kidney Pancreas Thymus
Heart Ovary Testis
Lymph nodes Spleen
EwS
Neuro-
blastoma
GIST
Ca
nc
er
N
or
m
a
l t
is
su
es
Osteo-
sarcoma
Leiomyo-
sarcoma
Rhabdomyo-
sarcoma
Lipo-
sarcoma
Synovial
sarcoma
12
10
8
6
SO
X6
 IR
S
4
2
0
600
400
SO
X6
 
ex
pr
es
sio
n 
in
te
ns
ity
(na
tur
a
l s
ca
le
)
200
0
AS
PS
 (13
)
AS
PS
 (3)
Ew
S (
70)
Ew
S (
73)
GI
ST
 (61
)
GI
ST
 (16
)
Le
iom
yo
sa
rc
om
a 
(50
)
Lip
os
arc
om
a (5
0)
Ne
ph
rob
las
tom
a (5
0)
Ne
uro
bla
sto
ma
 (49
)
Os
teo
sa
rco
ma
 (40
)
Rh
ab
do
my
os
ar
co
m
a 
(10
1)
Sy
no
via
l s
arc
om
a (3
4)
Le
iom
yo
sa
rc
om
a 
(13
)
Lip
os
arc
om
a (1
9)
Ne
ph
rob
las
tom
a (2
0)
Ne
uro
bla
sto
ma
 (17
)
Os
teo
sa
rco
ma
 (14
)
Rh
ab
do
my
os
ar
co
m
a 
(11
)
Sy
no
via
l s
arc
om
a (1
1)
Ad
ren
al 
gla
nd
 (19
)
Bo
ne
 m
arr
ow
 (25
)
En
do
me
triu
m 
(23
)
Es
op
ha
gu
s (1
4)
Fa
t (2
5)
Ga
llbl
ad
de
r (4
)
He
art
 (10
)
Kid
ne
y (1
4)
Liv
er
 (22
)
Lu
ng
 (25
)
Ly
m
ph
 no
de
s (5
)
Ov
ar
y (1
3)
Pa
nc
re
as
 (4)
Pr
os
tat
e (1
4)
Sk
in 
(25
)
Sp
lee
n (1
3)
Te
sti
s (1
0)
Th
ym
us
 (10
)
Ad
ren
al 
gla
nd
 (3)
Bo
ne
 m
arr
ow
 (3)
En
do
me
triu
m 
(3)
Es
op
ha
gu
s (3
)
Fa
t (3
)
Ga
llbl
ad
de
r (3
)
He
art
 (3)
Kid
ne
y (3
)
Liv
er
 (3)
Lu
ng
 (3)
Ly
m
ph
 no
de
s (3
)
Ov
ar
y (3
)
Pa
nc
re
as
 (3)
Pr
os
tat
e (3
)
Sk
in 
(3)
Sp
lee
n (3
)
Te
sti
s (3
)
Th
ym
us
 (3)
Fig. 1 SOX6 is highly but variably expressed in EwS. a SOX6 expression levels (Affymetrix microarrays) in EwS tumors, nine additional sarcoma or
pediatric tumor entities, and 18 normal tissue types. Data are represented as dot plots, horizontal bars represent medians. The number of biologically
independent samples per group (n) is given in parentheses. ASPS, alveolar soft part sarcoma; GIST, gastrointestinal stromal tumor. b Validation of SOX6
protein expression by IHC in the same tissue types as shown in (a). Immuno Reactive scores (IRS) are presented as dot plots. Horizontal bars represent
medians. The number of biologically independent samples per group (n) is given in parentheses. c Representative micrographs of the IHC stains from
samples of the same tumor entities or normal tissue types indicated in (b); scale bars= 20 µm. Source data are provided as a Source Data file.
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non-targeting control sipool (sipCtrl) after 96 h. In these
experiments, we noted a significant reduction of the viable cell
count in all EwS cell lines in standardized cell counting
experiments (including the supernatant) (Supplementary Fig. 3b).
Interestingly, sipool-mediated silencing of SOX6 had no effect on
proliferation of A673 and EW7 cell lines, which only express low
baseline levels of SOX6 (Supplementary Fig. 1a, Supplementary
Fig. 3b). In accordance, Dox-induced long-term SOX6 knock-
down significantly reduced the 2D clonogenic and 3D sphere-
formation capacities of the highly SOX6 expressing EwS cell lines
RDES and TC-32 as compared to controls (Dox (−) and shCtrl)
(Fig. 3c, Supplementary Fig. 3c), while SOX6 silencing in the
SOX6-low expressing cell line A673 had no effect on sphere-
formation capacity (Fig. 3c). To test whether this effect was
mediated via alteration of the cell cycle, we carried out flow
cytometric assays with propidium iodide (PI). In serum-starved
and thus G0-synchronized cells, we observed a significant delay in
cell cycle progression 20 h after re-addition of serum in SOX6-
silenced cells (Supplementary Fig. 3d).
Since ~85% of all clinical EwS tumors arise in bone1, we
examined the effect of SOX6 silencing in a 3D in vitro mineralized
bone model containing viable human osteoblasts26,27. Similar to
our previous in vitro assays, knockdown of SOX6 reduced growth
of EwS cells in this 3D bone model (Supplementary Fig. 3e).
Interestingly, this effect was accompanied by a reduced expres-
sion of the proliferation marker Ki67 (Supplementary Fig. 3e),
which further supported the involvement of SOX6 in cell cycle
progression.
To assess the potential contribution of SOX6 to EwS tumor
growth in vivo, we performed xenograft experiments by injecting
SOX6
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Fig. 2 EWSR1-FLI1 induces SOX6 expression via an intronic GGAA-mSat. a EWSR1-FLI1 and SOX6 expression (qRT-PCR) in A673/TR/shEF1 cells after
addition of Dox. Horizontal bars represent means, n= 3 biologically independent experiments for time points 0 h, 72 h and 168 h, n= 6 biologically
independent experiments for the time point 96 h. P values determined by two-sided Mann–Whitney test. EWSR1-FLI1: 72 h (P= 0.012), 96 h (P= 0.0007),
168 h (P= 0.012); SOX6: 72 h (P= 0.017), 96 h (P= 0.001), 168 h (P= 0.017). b Left: EWSR1-FLI1 and SOX6 expression (Affymetrix microarrays) in A673/
TR/shEF1 xenografts after 96 h of Dox-treatment. Horizontal bars represent means, n= 3 biologically independent xenografts per group. P value
determined via two-sided independent one-sample t-test (EWSR1-FLI1: P= 0.002, SOX6 P= 0.028). Right: Representative immunohistological staining for
(EWSR1-)FLI1 and SOX6. Scale bar= 20 µm. c SOX6 expression (Affymetrix microarrays) in embryoid bodies after ectopic EWSR1-FLI1 expression.
Horizontal bars represent means, n= 3 biologically independent samples per group. P value determined via unpaired two-sided t-test with Welch’s
correction (P= 0.002). d Integrated genomic view of DNAse I hypersensitivity (HS) and ChIP-Seq data for EWSR1-FLI1 and H3K27ac in EwS cells
transfected with shRNA against EWSR1-FLI1 (shEF1) or control shRNA (shGFP). e Relative enhancer activity of the SOX6-associated GGAA-mSat in A673/
TR/shEF1 cells (−/+ Dox). Horizontal bars represent means, n= 4 biologically independent experiments. P value determined via two-sided
Mann–Whitney test (P= 0.029). f Correlation of the average enhancer activity of both alleles of the SOX6-associated GGAA-mSat and the average SOX6
levels across eight EwS cell lines (TC-32 set as reference). The color code indicates the average number of consecutive GGAA-repeats of both alleles. P
value determined via two-tailed Pearson correlation test, n= 4 biologically independent experiments. All error bars represent SEM. ***P < 0.001, **P < 0.01,
*P < 0.05. Source data are provided as a Source Data file.
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two different EwS cell lines with Dox-inducible shRNAs against
SOX6 or control shRNA subcutaneously into the flanks of NSG
mice. While no effect of Dox-treatment was apparent in EwS cell
lines expressing the non-targeting control shRNA, we noted a
strong and consistent reduction of tumor growth upon SOX6
knockdown in both shRNA constructs and both cell lines
(Fig. 3d). The knockdown of SOX6 was confirmed ex vivo in
xenografts by qRT-PCR (Supplementary Fig. 3f) and by
immunohistochemistry (IHC) (Fig. 3e). Immunohistological
assessment showed that SOX6 silencing was associated with a
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significant reduction of proliferation as indicated by Ki67 staining
(Supplementary Fig. 3g) and numbers of mitotic cells per high-
power field (HPF) (Fig. 3f), confirming the in vitro findings on
SOX6 and cell cycle progression. In contrast, no significant
differences in cleaved caspase 3 (Fig. 3g) and Annexin V staining
(Supplementary Fig. 3h) were observed suggesting that the
apparent reduction of tumor growth was not mediated by
apoptotic cell death.
Notably, SOX6 protein expression was significantly
positively correlated with the speed of tumor growth and Ki67
immunoreactivity in EwS patient-derived xenograft (PDX)
models (Fig. 3h), in which we observed a broad range of SOX6
expression levels similar to that in primary EwS tumors (Fig. 1a,
b). In line with this finding, SOX6 knockdown completely
abolished the growth of TC-32/TR/shSOX6 EwS cells in an
orthotopic tibial bone injection model in vivo (Fig. 3i).
Among the proliferation-associated genes downregulated after
SOX6 knockdown (Fig. 3b), three genes (CDCA3, DEPDC1 and
E2F8) appeared as plausible candidate genes to promote the pro-
proliferative phenotype of SOX6, as they were previously shown
to be involved in cell cycle progression28–30.
In accordance, knockdown of any one of these genes with
specific sipools in RDES and TC-32 EwS cells phenocopied, at
least in part, the anti-proliferative effect of SOX6 knockdown
(Supplementary Fig. 3i,j).
Collectively, these results highlight a contribution of SOX6 to
proliferation, clonogenic growth and tumorigenicity of EwS cells
in vitro and in vivo.
SOX6 expression confers sensitivity toward Elesclomol. To
explore whether high SOX6 levels could constitute a specific
vulnerability of EwS that may be exploited therapeutically, we
interrogated a published gene expression dataset with matched
drug-response data comprising up to 22 EwS cell lines31. To
this end, we calculated for all 264 tested drugs the Pearson cor-
relation coefficient and its statistical significance of the corre-
sponding IC50 values with the observed SOX6 expression levels
across EwS cell lines (Fig. 4a). Among the top seven drugs, Ele-
sclomol (N-malonyl-bis (N-methyl-N-thiobenzoyl hydrazide)
(rPearson= –0.565; P= 0.014) was the only drug, which effectively
could inhibit EwS growth at a nanomolar range (median IC50
across cell lines ~25 nM) (Fig. 4b). Elesclomol is a potent oxi-
dative stress inducer, which can bind copper in the Cu(II) state.
The Elesclomol–copper complex then undergoes a redox reaction,
and copper is reduced to the Cu(I) state. In turn, this
phenomenon produces free radicals by a Fenton reaction32,33. In
cancer cells, the elevation of oxidative stress levels beyond a tol-
erable threshold exerts pro-apoptotic effects34. Indeed, in vali-
dation drug-response assays, Elesclomol strongly decreased
viability of EwS cells with high SOX6 levels while the osteo-
sarcoma cell line SAOS-2 and non-transformed human primary
MSC line MSC-52 that exhibit low SOX6 expression levels were
relatively resistant (Fig. 4c, d). Likewise, the SOX6-low expressing
EwS cell line A673 exhibited a similarly low sensitivity toward
Elesclomol than SAOS-2 and MSC-52 (Fig. 4c, d). The high
sensitivity of SOX6-high expressing EwS cells toward Elesclomol
appeared to be independent of proliferation under normal con-
ditions, since the osteosarcoma cell line SAOS-2 and the SOX6-
low expressing EwS cell line A673 proliferated even more than the
tested SOX6-high expressing EwS cells (Fig. 4e). Yet, knockdown
of SOX6 in RDES and TC-32 EwS cells significantly diminished
their sensitivity toward Elesclomol (Fig. 4f), pointing to a func-
tional role of SOX6 in Elesclomol sensitivity.
Consistent with a prior report in other cancer cell lines34,
Elesclomol strongly induced apoptosis in EwS cell lines in vitro
when treated with corresponding IC50 concentrations (Fig. 4g),
without affecting SOX6 expression levels (Supplementary Fig. 4a).
In accordance, intravenous administration of Elesclomol for nine
days reduced local tumor growth of TC-32 EwS xenografts in vivo
(Fig. 4h), which was accompanied by induction of apoptosis and
cell death as indicated by increased numbers of cells positive for
cleaved caspase 3 (Fig. 4i), and more necrotic tumor area (Fig. 4j).
Of note, mice treated with Elesclomol did not exhibit overt
adverse effects such as weight-loss (Supplementary Fig. 4b).
Similar to these in vivo models, Elesclomol-treatment strongly
reduced growth of EwS cells compared to DMSO controls in a 3D
in vitro mineralized bone model, and strongly induced apoptosis
as evidenced by staining for cleaved caspase 3 (Fig. 4k).
In sum, these results demonstrate that SOX6 expression in EwS
cells confers a proliferation-independent sensitivity toward the
oxidative stress-inducing small-molecule Elesclomol.
Elevated oxidative stress mediates Elesclomol sensitivity. Since
Elesclomol can induce oxidative stress, we investigated whether
Elesclomol-treatment modulates oxidative stress in EwS cell lines
and why EwS cells are sensitive to Elesclomol. Indeed, in both
EwS cell lines, treatment of RDES and TC-32 cells with Ele-
sclomol (10 nM) significantly induced oxidative stress compared
to control (DMSO) as determined by analysis of DCF-DA to DFA
conversion (Fig. 5a). Since Elesclomol may be able to interact
Fig. 3 SOX6 promotes proliferation of EwS cells in vitro and in vivo. a Representative SOX6 Western blot of n= 3 biologically independent replicates.
b Top: Volcano plot of differentially expressed genes. Bottom: Representative GSEA plots. NES, normalized enrichment score; NOM, nominal P value
(determined by two-sided permutation testing without adjustment for multiple testing)64; FDR, false discovery rate. c Sphere index after SOX6 knockdown.
Horizontal bars represent means, n= 3 biologically independent experiments. P values determined via two-sided Mann–Whitney test. RDES: shSOX6_2
(P≤ 0.0001), shSOX6_3 (P= 0.018); TC-32: shSOX6_2 (P≤ 0.0001), shSOX6_3 (P≤ 0.0001). Representative micrographs, scale bar= 1 mm. d Growth
of EwS xenografts (arrow= start of Dox-treatment). Data are represented as means (n indicates the number of biologically independent animals/group,
TC-32: shCtrl (n= 4), shSOX6_2 (Dox(–) n= 6, Dox(+) n= 3, P= 0.048), shSOX6_3 (n= 5, P= 0.032); RDES: shCtrl (Dox(–) n= 5, Dox(+) n= 6),
shSOX6_2 (Dox(–) n= 4, Dox(+) n= 5, P= 0.019), shSOX6_3 (Dox(–) n= 4, Dox(+) n= 3, P= 0.029)). P values determined via two-sided
Mann–Whitney test. e Representative IHC staining, scale bar= 20 µm. f Relative number of mitoses. Horizontal bars represent means (n indicates the
number of biologically independent animals/group, TC-32: shCtrl (n= 4), shSOX6_2 (Dox(–) n= 6, Dox(+) n= 3, P= 0.019), shSOX6_3 (n= 5, P=
0.029); RDES: shCtrl (Dox(–) n= 5, Dox(+) n= 6), shSOX6_2 (Dox(–) n= 4, Dox(+) n= 5, P= 0.024), shSOX6_3 (Dox(–) n= 4, Dox(+) n= 3, P=
0.008)). P values determined via two-sided Mann–Whitney test. g Relative cleaved caspase 3 positivity. Horizontal bars represent means (n indicates the
number of biologically independent animals/group, TC-32: shCtrl (n= 4), shSOX6_2 (Dox(–) n= 6, Dox(+) n= 3), shSOX6_3 (n= 5); RDES: shCtrl (Dox
(–) n= 5, Dox(+) n= 6), shSOX6_2 (Dox(–) n= 4, Dox(+) n= 5), shSOX6_3 (Dox(–) n= 4, Dox(+) n= 3)). h Correlation of time of growth of PDX
models or Ki67 positivity with SOX6 expression (n= 8 biologically independent PDX). Lines indicate linear regressions. P values determined by two-sided
Pearson correlation test. i Event-free survival in orthotopic xenografts, n= 8 biologically independent animals/group. Representative micrograph of the
injection site (Dox (–)), scale bar= 1000 µm. P values determined via Mantel–Haenszel test (P≤ 0.0001). All error bars represent SEM. ****P≤ 0.0001,
***P < 0.001, **P < 0.01, *P < 0.05. Source data are provided as a Source Data file.
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with the electron transport chain and to strongly induce intra-
mitochondrial reactive oxygen species (mito-ROS)32,33, we
stained EwS cells after Elesclomol-treatment with MitoSOX Red,
which can detect mitochondrial superoxide anions35, and nor-
malized the resulting MitoSOX Red fluorescence signal to the
mitochondrial mass as determined by MitoTracker Green
stains35. Indeed, we found that Elesclomol-treatment significantly
induced the relative fluorescence signal for MitoSOX Red
(Fig. 5b), which may suggest that at least part of the oxidative
stress induced by Elesclomol is derived from mito-ROS.
To test whether elevated oxidative stress levels play a role in the
capacity of Elesclomol to kill EwS cells, we carried out drug-
response assays in the presence/absence of the antioxidants N-
acetyl cysteine (Nac)36 and Tiron37. In both EwS cell lines, Nac-
or Tiron-treatment resulted in significantly reduced conversion of
DCF-DA to DCF (Fig. 5c) and decreased Elesclomol sensitivity
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(Fig. 5d), indicating that this drug may exert its pro-apoptotic
effect in EwS to a certain degree via induction of oxidative stress
over a tolerable threshold.
In line with this hypothesis, Dox-induced knockdown of SOX6
reduced the rate of DCF-DA to DFA conversion as well as the
relative levels of MitoSOX Red (Fig. 5e, f) in both EwS cell lines
(RDES and TC-32) and for both shRNA constructs, which was
not observed in corresponding controls (shCtrl). To functionally
validate the potential oxidative stress-dependent sensitivity
toward Elesclomol conferred by SOX6 on EwS cells, we
performed rescue experiments. In those, we noted that addition
of the potent oxidative ROS-inducer H2O2 on the SOX6-silenced
EwS cells could fully restore the sensitivity of these cell lines
toward Elesclomol (Fig. 5g), while having no effect on viability of
EwS cells that were not treated with Elesclomol (Supplementary
Fig. 5a).
Together, these data suggested that SOX6 is involved in
oxidative stress regulation in vitro and in vivo, and that the
cellular oxidative stress levels may influence the sensitivity of EwS
toward Elesclomol.
SOX6-mediated TXNIP expression causes Elesclomol sensi-
tivity. To explore possible links between SOX6, oxidative stress,
and Elesclomol sensitivity in EwS cells, we reassessed our micro-
array data obtained from EwS cells with/without knockdown of
SOX6. Of note, TXNIP (thioredoxin interacting protein)— a key
inhibitor of the thioredoxin antioxidant system38,39—was the
second most strongly downregulated gene after SOX6 silencing in
this discovery experiment (Supplementary Data 2).
We further investigated this finding by analyzing additional
microarray gene expression data generated on the same
microarray platform in 18 EwS cell lines (triplicate measurements
per cell line). In this dataset, we found a significant positive
correlation (rPearson= 0.559, P= 0.016) of the average SOX6 and
TXNIP mRNA expression levels across EwS cell lines (Fig. 6a).
To corroborate the link between SOX6 and TXNIP, we carried
out multiple independent SOX6 knockdown experiments in
which we detected a consistent downregulation of TXNIP at the
mRNA and protein level in vitro (Fig. 6b). In addition, we found
a significant downregulation of TXNIP in vivo by immunohis-
tochemistry in xenografts with SOX6 knockdown (Fig. 6c).
Interestingly, direct siRNA-mediated knockdown of TXNIP in
EwS cells (Fig. 6d) significantly reduced the conversion rate of
DCF-DA to DCF (Fig. 6e), and the relative levels of MitoSOX Red
fluorescence (Fig. 6f). In accordance, direct knockdown of TXNIP
reduced the sensitivity of EwS cells toward Elesclomol (Fig. 6g) to
a similar extent than SOX6 knockdown (Fig. 4f). Even more
strikingly, inducible re-expression of TXNIP in SOX6-silenced
EwS cells onto ‘physiological’ levels was sufficient to rescue ~66%
of the sensitivity of these EwS cells toward Elesclomol (Fig. 6h).
Of note, inducible overexpression of SOX6 in the SOX6-low
expressing EwS cell line A673 was accompanied by a significant
induction of TXNIP expression and increased sensitivity toward
Elesclomol (P < 0.01) (Supplementary Fig. 5b, c).
Taken together, these data provide evidence that the EWSR1-
FLI1-induced strong upregulation of SOX6 contributes, at least in
part, via upregulation of TXNIP and oxidative stress levels to the
high sensitivity of EwS cells toward the oxidative stress-inducing
drug Elesclomol (Fig. 6i).
Discussion
EwS is a highly aggressive bone or soft-tissue cancer, possibly
descending from osteo-chondrogenic progenitors. Since the
transcription factor SOX6 is crucial for endochondral ossification
and thus for bone development16,40, we aimed at analyzing its
role in EwS.
Our results show that SOX6 is a direct EWSR1-FLI1 target gene
that is highly but variably overexpressed at the mRNA and protein
level in EwS as compared to most normal tissues and other can-
cers. However, we found no correlation of copy number variations
and differences in promoter methylation with SOX6 expression
levels in EwS tumors. In contrast, we identified an intronic SOX6-
associated GGAA-mSat that was bound by EWSR1-FLI1 in vivo
and which exhibited strong length- and EWSR1-FLI1-dependent
enhancer activity in EwS cell lines. Thus, it is tempting to spec-
ulate that the observed inter-tumor heterogeneity in SOX6
expression of EwS tumors and EwS cell lines is likely caused by
inter-individual differences in the number of consecutive GGAA-
repeats at this SOX6-associated GGAA-mSat. These findings are in
line with recent observations for other direct EWSR1-FLI1 target
genes such as EGR2, MYBL2, and NR0B1 whose variable expres-
sion in EwS tumors is caused by inter-individual differences in
Fig. 4 SOX6 expression confers sensitivity toward Elesclomol. a Correlated expression/drug-response data31. Dark gray/pink= top-7 drugs (two-tailed
Pearson correlation without adjustment for multiple testing). b IC50 of top-7 drugs (n indicates the number of independent cell lines: Elesclomol, n= 18,
P= 0.015; Fedratinib, n= 19, P= 0.012; PHA-793887, n= 19, P= 0.004; Rucaparib, n= 18, P= 0.003; Serdemetan, n= 17, P= 0.011; Imatinib, n= 18,
P= 0.017; Olaparib, n= 20, P= 0.005). Horizontal bars represent medians. c Relative viability (n indicates the number of biologically independent
experiments/cell line: RDES (black) n= 10, TC-32 (gray) n= 9, A673 (orange) n= 4), SAOS-2 (green) n= 4, MSC-52 (light green) n= 3). d SOX6
expression. Horizontal bars represent means (n indicates the number of biologically independent experiments/cell line: TC-32 n= 8, RDES n= 8, A673
n= 4 (P= 0.004), SAOS-2 n= 3 (P= 0.012), MSC-52 n= 3 (P= 0.012)). P values determined via two-sided Mann–Whitney test. e Cell viability.
Horizontal bars represent means (n indicates the number of biologically independent experiments/cell line: TC-32 n= 12, RDES n= 12, A673 n= 4
(P= 0.004), SAOS-2 n= 5 (P= 0.006), MSC-52 n= 5 (P= 0.006)). P values determined via two-sided Mann–Whitney test. f Elesclomol-IC50.
Horizontal bars represent means (n indicates the number of biologically independent experiments/cell line: TC-32: shCtrl n= 4, shSOX6_2 n= 9 (P≤
0.0001), shSOX6_3 n= 6 (P= 0.012); RDES: shCtrl n= 4, shSOX6_2 n= 10 (P= 0.0007), shSOX6_3 n= 5 (P= 0.026)). P values determined via two-
sided Mann–Whitney test. g Annexin-V-positivity. Horizontal bars represent means, n= 10 biologically independent experiments. P values determined via
unpaired two-sided t-test with Welch-correction; TC-32 (P= 0.0009), RDES (P= 0.009). h EwS-xenografts under Elesclomol-treatment (arrows). Data
represent means, n= 5 biologically independent animals/condition. P value determined via two-sided Mann–Whitney test (P= 0.046). i Left: CC3-
positivity. Horizontal bars represent means, n= 5 biologically independent xenografts/condition. P value determined via one-sided Mann–Whitney test
(P= 0.044). Right: Representative micrographs, scale bar= 100 µm. j Left: Relative necrosis. Horizontal bars represent means, n= 5 biologically
independent xenografts/condition. Right: Representative micrographs, scale bar= 900 µm. k Left: Relative cellularity. Horizontal bars represent means,
n= 3 biologically independent experiments. Representative micrographs, scale bar= 50 µm. P value determined via two-sided Mann–Whitney test (P≤
0.0001). Right: CC3/DAPI-positivity. Horizontal bars represent means, n= 3 biologically independent experiments. Representative micrographs, scale
bar= 50 µm. P value determined via two-sided Mann–Whitney test (P= 0.002). All error bars represent SEM. ****P≤ 0.0001, ***P < 0.001, **P < 0.01,
*P < 0.05. Source data are provided as a Source Data file.
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GGAA-repeat numbers of the corresponding enhancer-like
GGAA-mSat21,22,41.
Depending on the cellular context, SOX6 may act as a splicing
factor23,24 or as transcriptional regulator40. In transcriptome
profiling experiments that comprised >285,000 transcripts and
isoforms, we did not observe a strong contribution of SOX6 to
alternative splicing in EwS. Instead, we identified a broad gene
expression alteration after SOX6 silencing, pointing to a more
pronounced role of SOX6 as a transcription factor in EwS.
Especially the downregulated DEGs after SOX6 knockdown were
significantly enriched for gene sets involved in proliferation and
cell cycle progression. These changes in the cellular transcriptome
were mirrored in functional in vitro and in vivo experiments. The
strong pro-tumorigenic function of SOX6 in EwS is intriguing
since in other cancer entities such as esophageal squamous cell
carcinoma and hepatocellular carcinoma SOX6 was reported to
act as a tumor suppressor42,43. However, in EwS, knockdown of
SOX6 strongly reduced anchorage-independent growth and
tumorigenicity, which was accompanied by delayed transition
through cell cycle phases, reduced mitotic index and decreased
expression of the proliferation marker Ki67. Thus, our results
suggest that SOX6 may also have oncogenic properties, and that
its oncogenic or tumor-suppressive function may depend on the
cellular context. In this regard, it is interesting to note that other
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direct EWSR1-FLI1 target genes, such as EGR2, MYBL2, and
NR0B1, which are driven by GGAA-mSats, are also critical
mediators of EwS tumorigenesis21,22,44.
Since therapeutic options for EwS patients are urgently
required1, we investigated whether the high expression of SOX6
in EwS may provide a vulnerability that could be exploited
therapeutically. Indeed, we discovered that high expression of
SOX6 confers hypersensitivity toward the small-molecule Ele-
sclomol. While Elesclomol was shown to inhibit cancer cell
growth in vitro at micro-molar concentrations, in melanoma,
breast cancer and leukemia cell lines32,33,45,46 we noted a much
higher sensitivity of EwS cells toward Elesclomol with IC50 values
in the nanomolar range. These observations suggest that the
higher sensitivity of EwS toward Elesclomol may be caused by the
relatively higher expression of SOX6 in EwS compared to other
cancers such as osteosarcoma and melanoma (Supplementary
Fig. 4c). In support of this hypothesis, Elesclomol-treatment in
combination with paclitaxel had only moderate effect on outcome
of unselected patients affected by malignant melanoma in phase
II and III clinical trials47,48, and may have shown higher efficacy
when preselecting patients with higher SOX6 levels or higher
intracellular oxidative stress levels.
Since clinical development of Elesclomol has been dis-
continued, we explored whether other compounds could serve as
alternatives. Interestingly, among three so-called oxidative stress
inducers (BRD56491, DC_AC50, and Menadione), BRD56491
and DC_AC50 failed to induce oxidative stress and subsequent
cell death at physiologically relevant concentrations in EwS cells
(IC50 > 20 µM) (Supplementary Fig. 6a). In contrast, Menadione
was able to induce oxidative stress (including mito-ROS) (Sup-
plementary Fig. 6b) and to decrease the viability of EwS cells
expressing high SOX6 levels, albeit only at ~1500-fold higher
concentrations compared to Elesclomol (IC50 ~6 µM for Mena-
dione vs. ~4 nM for Elesclomol) (Supplementary Fig. 6c), which
may highlight the potency of Elesclomol.
Since many cancer types including EwS display an oxidative
stress phenotype characterized by higher oxidative stress levels
than normal tissues49,50, cancer cells tend to be more sensitive
toward further increases in oxidative stress than nonmalignant
cells51. Previous reports demonstrated that Elesclomol can
induce oxidative stress beyond a tolerable threshold triggering
apoptosis32,34,52. In line with these findings, we observed an
increase of DCF-DA to DCF conversion and relative MitoSOX
Red fluorescence followed by apoptosis after Elesclomol-treatment
in vitro and in vivo in EwS cells. The apoptotic effect appeared to
be dependent on the baseline intracellular oxidative stress levels
because knockdown of SOX6 and concomitant downregulation of
oxidative stress (as measured by DCF-DA to DCF conversion and
relative MitoSOX Red fluorescence) or pre-treatment of EwS cells
with the antioxidants Nac and Tiron diminished the sensitivity of
EwS cells toward Elesclomol, whereas addition of the ROS-inducer
H2O2 rescued the SOX6 knockdown effect on Elesclomol
sensitivity.
The elevated intracellular oxidative stress and mito-ROS levels
as well as the associated hypersensitivity of SOX6-high expressing
EwS cells toward Elesclomol can be explained, at least in part, by
the SOX6-mediated upregulation of TXNIP. In fact, TXNIP
knockdown in EwS cells was associated with decreased conver-
sion rates of DCF-DA to DCF and lower levels of relative
MitoSOX Red fluorescence, which might be caused by its
potential inhibitory function on the thioredoxin (TRX) anti-
oxidant system that plays an essential role in buffering intracel-
lular oxidative stress53,54. In our rescue experiments, we noted
that restoration of TXNIP expression (Fig. 6h) in SOX6-silenced
EwS cells could rescue ~66% of the Elesclomol sensitivity. These
data indicate that TXNIP is an important downstream mediator
of the SOX6-induced Elesclomol sensitivity of EwS cells, but also
suggest that other factors may play a role.
Besides, the role of TXNIP in EwS may extend beyond the TRX
antioxidant system, since TXNIP has also been reported to
impact on glucose and lipid metabolism38. While the potentially
pro-proliferative role of TXNIP in EwS remains to be fully elu-
cidated, it should be noted that in other cancers including
hepatocellular, breast, and bladder carcinoma as well as leukemia,
TXNIP has been reported to act as a tumor suppressor39, indi-
cating that this protein may, like SOX6, either promote or inhibit
tumor growth depending on the cellular context.
Our data suggest that oxidative stress-inducing drugs such as
Elesclomol could offer a therapeutic option for EwS patients with
high SOX6 expression levels. Additionally, SOX6 may serve as a
biomarker to predict the efficacy of Elesclomol-treatment in EwS,
and perhaps other cancer types. Interestingly, Elesclomol-
treatment has been shown to potentiate the pro-apoptotic effect
of oxidative stress-dependent chemotherapeutic drugs such as
doxorubicin in breast cancer46. Since doxorubicin is part of
current standard treatment regimens for EwS patients, it is
tempting to speculate that Elesclomol-treatment may also serve as
an enhancer for doxorubicin treatment in EwS, even in patients
Fig. 5 Elesclomol sensitivity is induced by oxidative stress levels. a Representative histogram (left) and quantification (right) of DCF-DA fluorescence in
TC-32 cells after Elesclomol-treatment (10 nM, pink) compared to DMSO control (gray). Horizontal bars represent means, n= 8 biologically independent
experiments. P values determined via two-sided independent one-sample t-test (TC-32 (P≤ 0.0001), RDES (P≤ 0.0001). b MitoSOX Red /MitoTracker
Green ratio in EwS cells after Elesclomol-treatment (10 nM). Horizontal bars represent means, n= 3 biologically independent experiments. P values
determined via two-sided independent one-sample t-test (TC-32 (P= 0.006), RDES (P= 0.025). c Relative DCF-DA fluorescence in EwS cells after
antioxidant-treatment (0.01 mM Nac or 0.1 mM Tiron). Horizontal bars represent means (n indicates the number of biologically independent experiments
per condition: Nac: TC-32 (n= 4, P= 0.008), RDES (n= 4, P= 0.018), Tiron: TC-32 (n= 3, P= 0.005), RDES (n= 3, P= 0.045)). P values determined via
two-sided independent one-sample t-test. d Elesclomol IC50 in EwS cells after pre-treatment with Nac (0.01 mM) or Tiron (0.1 mM). Horizontal bars
represent means (n indicates the number of biologically independent experiments per condition: Nac: TC-32 (n= 5, P= 0.032), RDES (n= 5, P= 0.016);
Tiron: TC-32 (n= 4, P= 0.029), RDES (n= 4, P= 0.029)). P values determined via two-sided Mann–Whitney test. e Representative histogram of DCF-DA
fluorescence (left) and quantification (right) in TC-32/TR/shSOX6_2 cells 96 h after SOX6 knockdown. Horizontal bars represent means, n= 5 biologically
independent experiments. P values determined via two-sided independent one-sample t-test (TC-32: shSOX6_2 (P= 0.001), shSOX6_3 (P= 0.005);
RDES: shSOX6_2 (P= 0.025), shSOX6_3 (P= 0.001)). f Relative MitoSOX Red/MitoTracker Green ratios in EwS cells 96 h after SOX6 knockdown.
Horizontal bars represent means, n= 3 biologically independent experiments. P values determined via two-sided independent one-sample t-test (TC-32:
shSOX6_2 (P= 0.008), shSOX6_3 (P= 0.014); RDES: shSOX6_2 (P= 0.038), shSOX6_3 (P= 0.006)). g Relative Elesclomol IC50 in EwS cells after
SOX6 knockdown and treatment with H2O2 (30 µmol/l) for 72 h. Horizontal bars represent means (n indicates the number of biologically independent
experiments per condition: TC-32: shSOX6_2 (n= 6, P= 0.002) shSOX6_3 (n= 5, P= 0.032); RDES: shSOX6_2 (n= 6, P= 0.041), shSOX6_3 (n= 5;
P= 0.008)). P values determined via two-sided Mann–Whitney test. All error bars represent SEM. ****P≤ 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
Source data are provided as a Source Data file.
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with relatively low intratumoral SOX6 levels. However, as Ele-
sclomol targets actively respiring mitochondria, it may have less
efficacy in hypoxic conditions33, which may be the case in large
hypoxic tumors.
In synopsis, we discovered that EWSR1-FLI1 hijacks SOX6 in
EwS, which promotes tumor growth and modulates intracellular
oxidative stress levels creating a therapeutic vulnerability toward
oxidative stress-inducing drugs. Our results exemplify how
aberrant activation of a developmental transcription factor by a
dominant oncogene can promote malignancy but provide
opportunities for targeted therapy.
Methods
Cell lines and cell culture conditions. The neuroblastoma cell line SK-N-AS as
well as HEK293T were purchased from ATCC. Human EwS cell lines and other cell
lines were provided by the following repositories and/or sources: A673 cells were
purchased from ATCC. MHH-ES1, RDES, RH-1, SK-ES1, and SK-N-MC and cells
were provided by the German collection of Microorganism and Cell Cultures
(DSMZ). CHLA-10, CHLA-25, CHLA-32, CHLA-57, CHLA-99, COG-E-352, TC-
32, TC-71, and TC-106 were kindly provided by the Children’s Oncology Group
(COG), and ES7, EW1, EW3, EW7, EW16, EW17, EW18, EW22, EW24, MIC,
ORS, POE, SK-PN-DW, SK-PN-LI, and STA-ET1 as well as rhabdomyosarcoma
(Rh4, Rh36) and neuroblastoma (TGW) cell lines cells were provided by O.
Delattre (Institute Curie, Paris). A673/TR/shEF1 cells were provided by J. Alonso
(Madrid, Spain)55. Human osteosarcoma cell lines SAOS-2 and U2OS were pro-
vided by DMSZ, and the MSC cell line MSC-52 was generated from bone marrow
of an EwS patient (provided by U. Dirksen; Essen, Germany). All cell lines were
cultured in RPMI-1640 medium with stable glutamine (Biochrom, Germany)
supplemented with 10% tetracycline-free fetal bovine serum (Sigma-Aldrich,
Germany), 100 U/ml penicillin and 100 µg/ml streptomycin (Merck, Germany) at
37 °C with 5% CO2 in a humidified atmosphere. Cell lines were routinely tested for
mycoplasma contamination by nested PCR, and cell line identity was regularly
verified by STR-profiling.
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RNA extraction, reverse transcription, and qRT-PCR. Total RNA was isolated
using the NucleoSpin RNA kit (Macherey-Nagel, Germany). 1 µg of total RNA was
reverse-transcribed using High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, USA). qRT-PCR reactions were performed using SYBR green Mas-
termix (Applied Biosystems) mixed with diluted cDNA (1:10) and 0.5 µM forward
and reverse primer (total reaction volume 15 µl) on a BioRad CFX Connect
instrument and analyzed using BioRad CFX Manager 3.1 software. Gene expres-
sion values were calculated using the 2−(ΔΔCt) method56 relative to the house-
keeping gene RPLP0 as internal control. Oligonucleotides were purchased from
MWG Eurofins Genomics (Germany) and are listed in Supplementary Table 2. The
thermal conditions for qRT-PCR were as follows: heat activation at 95 °C for 2 min,
DNA denaturation at 95 °C for 10 s, and annealing and elongation at 60 °C for 20 s
(50 cycles), final denaturation at 95 °C for 30 s.
Transient RNA interference (RNAi). POE, RDES, TC-32, A673, and EW7 cells
were transiently reversely transfected with Lipofectamine RNAiMAX according to
the manufacturer’s protocol (Invitrogen, USA) with either a non-targeting control
sipool (sipCtrl) or sipools specifically directed against CDCA3, DEPDC1, E2F8, or
SOX6 (all siTOOLs, Biotech, Germany) or short interfering RNA (siRNA) against
TXNIP (MWG Eurofins, Germany) (Supplementary Table 2) at a final con-
centration of 5–15 nM depending on the cell line and target gene. Cells were re-
transfected 48 h after the first transfection. All sipools consisted of 30 different
siRNAs directed against the target transcript, which eliminates off-target effects25.
Knockdown efficacy was validated by qRT-PCR and/or Western blot.
Cloning of GGAA-mSats and luciferase reporter assays. For luciferase reporter
assays, both alleles of a 1-kb fragment including the SOX6-associated GGAA-mSat
(hg19 coordinates: chr11: 16,394,850–16,395,749) were cloned from three highly
SOX6 expressing EwS cell lines (RDES, TC-32, POE) and three SOX6 moderately
(SK-N-MC, EW17, and ORS) and two SOX6 lowly expressing EwS cells (A673,
EW7) using GoTaq DNA Polymerase (Promega, Germany) and primer sequences
listed in Supplementary Table 2. The thermal conditions for touchdown (TD)-PCR
protocol were as follows: Initial denaturation: 95 °C for 2 min; denaturation 98 °C
for 10 s; annealing: 59−49 °C for 30 s (Tm (=59 °C)−5 °C+ 10 °C higher for TD-
PCR);− 1 °C every 2 cycles); extension: 72 °C for 1 min (2 × 10 cycles, and sub-
sequently another 20 cycles at an annealing temperature of 65 °C); final extension:
72 °C for 5 min. These fragments were cloned upstream of the SV40 minimal
promoter into the pGL3 luciferase reporter vector (Promega, #E1761, Germany) by
In-Fusion HD Cloning Kit (Clontech, Japan) according to the manufacturer’s
protocol. These vectors were used for transformation of Stellar Competent Cells
(Clontech); successfully transformed bacteria were selected using ampicillin
(Merck). Correct insertion of the vector was confirmed by colony PCR. The
number of consecutive GGAA-repeats for each allele and each cell line was
determined by commercial Sanger sequencing. The sequencing primer is listed in
Supplementary Table 2. The presence of additional genetic variation in the cloned
sequences apart from the SOX6-associated GGAA-mSat was ruled out by whole-
genome sequencing of the parental cell lines and confirmatory Sanger sequencing
of the cloned fragments. For reporter assays, 5 × 104 A673/TR/shEF1 cells per 24-
well were seeded in 600 µl medium and transfected with pGL3 luciferase reporter
vector and Renilla pGL3-Rluc (ratio, 100:1) using Lipofectamine LTX Reagent with
PLUS Reagent (Invitrogen). Four hours after transfection, the culture media was
replaced by media with/without (w/o) Doxycycline (Dox; 1 μg/ml; Merck). Cells
were lysed after 72 h and monitored with a dual luciferase assay system (Berthold,
Germany). Firefly luciferase activity was normalized to Renilla luciferase activity.
Analysis of copy number variation and promoter methylation. For analysis
of genomic copy numbers, publicly available DNA copy number data for EwS
tumors57 with corresponding RNA expression data (GSE34620 and GSE37371,
n= 32), were downloaded from the “soft-tissue cancer—Ewing sarcoma—FR”
project from the International Cancer Genome Consortium (ICGC) Data Portal
and Gene Expression Omnibus (GEO) of the NCBI, respectively. For the SOX6
locus, segment mean values were extracted from these data using Visual Basic for
Applications (VBA). The segment mean values were correlated with the log2-
transformed expression of the candidate gene. For CpG methylation analysis,
publicly available data on CpG methylation in 40 EwS tumors (GSE88826)58 with
corresponding RNA expression data (GSE34620) were downloaded from GEO. For
the SOX6 locus, the ratio of methylated versus unmethylated reads was calculated
for two CpG sites (CpG1 hg19: chr11:15994482; CpG2 hg19: chr11:15994519) in
each sample (n= 40) using VBA, which were covered by at least four reads.
Analysis of SOX6 expression levels in human embryoid bodies. Publicly
available gene expression microarray data for ectopic EWSR1-FLI1 expression in
human embryoid bodies generated on the Affymetrix HG-U133Plus2.0 array
(GSE64686)59 were normalized by Robust Multiarray Average (RMA)60 using
custom brainarray chip description files (CDF; ENTREZG, v19) yielding one
optimized probe-set per gene61.
Analysis of published DNase-Seq and ChIP-Seq data. ENCODE SK-N-MC
DNase-Seq (GSM736570) and ChIP-Seq data (GSE61944) were downloaded from
the GEO, processed and displayed in the UCSC genome browser. The following
samples were used in this study:
ENCODE_SKNMC_hg19_DNAseHS_rep1
GSM1517546_SKNMC.shGFP96.FLI1
GSM1517555_SKNMC.shFLI196.FLI1
GSM1517547_SKNMC.shGFP96.H3K27ac
GSM1517556_SKNMC.shFLI196.H3K27ac
GSM1517569_A673.shGFP48.FLI1
GSM1517572_A673.shFLI148.FLI1
GSM1517570_A673.shGFP48.H3K27ac
GSM1517573_A673.shFLI148.H3K27ac
Transcriptome and splicing analyses. To assess an impact of SOX6 on gene
expression and on alternative splicing in EwS, microarray analysis was performed.
To this end, 1.2 × 104 cells were seeded in wells of 6-well plates and treated with
Dox for 96 h (Dox-refreshment after 48 h). Thereafter, total RNA was extracted
with the ReliaPrep miRNA Cell and Tissue Miniprep System (Promega) and
transcriptome profiled at IMGM laboratories (Martinsried, Germany). RNA
quality was assessed with a Bioanalyzer and samples with RNA integrity numbers
(RIN) > 9 were hybridized to Human Affymetrix Clariom D microarrays. Data
were quantile normalized with Transcriptome Analysis Console (v4.0; Thermo
Fisher Scientific) using the SST-RMA algorithm. Annotation of the data was
performed using the Affymetrix library for Clariom D Array (version 2, human),
both on gene and exon level. DEGs with consistent and significant fold changes
(FCs) across shRNAs and cell lines were identified as follows: First, normalized
gene expression signal was log2 transformed. To avoid false discovery artifacts due
to the detection of only minimally expressed genes, we excluded all genes with a
lower or just minimally higher gene expression signal than that observed for ERG
(mean log2 expression signal of 6.05), which is known to be virtually not expressed
in EWSR1-FLI1 positive EwS cell lines62. Accordingly, only genes with mean log2
Fig. 6 SOX6-mediated TXNIP expression causes Elesclomol sensitivity. a Correlation of TXNIP and SOX6 expression in 18 EwS cell lines. The line
indicates the linear regression of the data (two-tailed Pearson correlation test, P= 0.016, rpearson= 0.559). b Top: Representative Western blot analysis
of TXNIP 96 h after SOX6 knockdown. GAPDH served as loading control. Bottom: Relative TXNIP expression (qRT-PCR). Horizontal bars represent means,
n= 3 biologically independent experiments. P values determined via two-sided Mann–Whitney test (all P= 0.002). c Top: representative micrographs
from EwS xenografts with/without SOX6 knockdown stained for TXNIP. Bottom: IRS for TXNIP (n indicates the number of biologically independent
xenografts per condition: TC-32: shCtrl (Dox(–) n= 3, Dox(+) n= 4), shSOX6_2/3 (Dox(–) n= 11, Dox(+) n= 8, P≤ 0.0001); RDES: shCtrl (Dox(–)
n= 4, Dox(+) n= 6), shSOX6_2/3 (Dox(–) n= 7, Dox(+) n= 8, P= 0.007). Horizontal bars represent medians. P values determined via two-sided
Mann–Whitney test. Scale bar= 20 µm. d Relative TXNIP expression (qRT-PCR) in TC-32 cells 96 h after TXNIP knockdown. Horizontal bars represent
means, n= 5 biologically independent experiments, P= 0.008. P value determined via two-sided Mann–Whitney test. e Relative DCF-DA fluorescence in
TC-32 cells after TXNIP knockdown. Horizontal bars represent means, n= 5 biologically independent experiments, P= 0.009. P value determined via two-
sided independent one-sample t-test. f MitoSOX Red/MitoTracker Green ratio in TC-32 cells after TXNIP knockdown. Horizontal bars represent means,
n= 4 biologically independent experiments, P= 0.012. P value determined via two-sided independent one-sample t-test. g Elesclomol IC50 upon TXNIP
knockdown in TC-32 cells. Horizontal bars represent means, n= 4 biologically independent experiments, P= 0.029. P value determined via two-sided
Mann–Whitney test. h Left: Relative mRNA expression in TC-32 EwS cells after 96 h of concomitant Dox-treatment (0.1 µg/ml) and Cumate-treatment
(5 µg/ml). Horizontal bars represent means, n= 5 biologically independent experiments, P= 0.008. Right: Relative Elesclomol IC50 in TC-32 cells 72 h
after Elesclomol-treatment and concomitant addition of Dox (0.1 µg/ml) and Cumate (5 µg/ml). Horizontal bars represent means, n= 5 biologically
independent experiments, P= 0.008. P values determined via two-sided Mann–Whitney test. i Schematic illustration of the EWSR1-FLI1-mediated effect of
SOX6 expression. All error bars represent SEM. ****P≤ 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. Source data are provided as a Source Data file.
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expression signals (w/o Dox condition) of at least 7 were further analyzed. The FCs
of the shControl samples and both specific shRNAs were calculated for each cell
line separately. Then the FCs observed in the respective shControl samples were
subtracted from those seen in the shSOX6 samples, which yielded the FCs for each
specific shRNAs in each cell line. Then these FCs were averaged to obtain the mean
FC per gene across shRNAs and cell lines. As the log2 FC for SOX6 was –1.486, we
assumed that downstream targets should also be strongly regulated. Consequently,
only genes with a minimum absolute log2 FC of 1 were considered as DEGs.
Additionally, the false discovery rate (FDR) was estimated for each gene using the
R package qvalue from BioConductor63. To identify enriched gene sets, genes were
ranked by their expression FC between the groups Dox (−/+), and a pre-ranked
GSEA (MSigDB v5.2, c2.cgp.all) with 1,000 permutations was performed64.
To assess the potential role of SOX6 in alternative splicing, we assumed that, if
RNA is not alternatively spliced, the ratio of each probe selection region (PSR)
expression measured on the Affymetrix microarray with and without SOX6
knockdown stays the same independently of up- or downregulation of the
corresponding gene. Hence, we calculated the additional FC between the
expression value of each PSR before and after SOX6 knockdown to the FC expected
by expression regulation assessed on the gene level. Of 539,385 PSRs with 47,851
matched genes in our analysis, 22,155 PSRs (10,754 genes) showed a consistent
positive or negative additional log2 transformed expression FC of ≥0.3. For 20,050
PSRs (10,179 genes) expression differences were significant (P ≤ 0.05) when
corrected for the FC on gene level. However, none of the PSRs remained significant
after Bonferroni correction for multiple testing. Gene expression data were
deposited at the GEO (accession code GSE120576).
For comparative analyses of SOX6 and TXNIP mRNA expression levels, total
RNA of 18 EwS cell lines (A673, CHLA-10, CHLA-25, EW1, EW22, EW24, EW3,
EW7, MHH-ES1, MIC, POE, RDES, RH-1, SK-ES1, SK-N-MC, TC-106, TC-32,
and TC-71) was assessed by Affymetrix Clariom D microarrays as described above
in triplicate measurements per cell line.
Generation of Dox-inducible shRNA-expressing cells. For long-term experi-
ments human EwS cell lines SK-N-MC, POE, RDES and TC-32 were transduced
with lentiviral pLKO-TET-ON all-in-one vector system (plasmid #21915,
Addgene) containing a puromycin-resistance cassette, and a tet-responsive element
for Dox-inducible expression of shRNA against EWSR1-FLI1 (shEF1), SOX6
(shSOX6) or a non-targeting control shRNA (shCtrl). Dox-inducible vectors were
generated according to a publicly available protocol65 using In-Fusion HD Cloning
Kit (Clontech) (Supplementary Table 2). Vectors were amplified in Stellar Com-
petent Cells (Clontech) and integrated shRNA was verified by Sanger sequencing.
The sequencing primer is listed in Supplementary Table 2. Lentiviral particles were
generated in HEK293T cells. Virus-containing supernatant was collected to infect
the human EwS cell lines. Successfully transduced cells were selected with 1.5 µg/ml
puromycin (InVivoGen, USA). The shRNA expression for SOX6 knockdown in
EwS cells was achieved by adding 0.1 µg/ml Dox every 48 h to the medium.
Generated cell lines were designated as SK-N-MC/TR/shEF1, POE/TR/shSOX6_1,
POE/TR/shSOX6_3, RDES/TR/shCtrl, RDES/TR/shSOX6_2, RDES/TR/shSOX6_3,
TC-32/TR/shCtrl, TC-32/TR/shSOX6_2, and TC-32/TR/shSOX6_3.
TXNIP rescue experiments. For rescue experiments, TC-32/TR/shSOX6_2 EwS
cells were additionally transduced with a Cumate-inducible overexpression system
based on the pCDH-CuO-MCS-EF1α-CymR-T2A-Puro SparQ™ All-in-one Clon-
ing and Expression Lentivector (System Biosciences, USA, QM800A-1-SBI)66. The
full-length cDNA of TXNIP (NM_006472) was PCR-amplified from a commercial
plasmid (GenScript, Hong Kong, OHu20973) and cloned into the multiple cloning
site. In addition, the puromycin-resistance gene was replaced by an eGFP coding
sequence cloned from pCMV-GFP plasmid (Addgene Plasmid #11153). The cor-
rect insertion of the full-length TXNIP cDNA was verified by Sanger sequencing.
The PCR and sequencing primers are listed in Supplementary Table 2. Successfully
transduced EwS cells were subsequently sorted by a fluorescence-activated cell
sorter (FACS). Re-expression of TXNIP in these EwS cells was achieved by addition
of 5 µg/ml Cumate to the culture medium (media change including Cumate
every 48 h).
Inducible overexpression of SOX6. SOX6 overexpression experiments were car-
ried out in the SOX6-low expressing EwS cell line A673. To this end, full-length
cDNA of SOX6 (NM_033326.3) was PCR-amplified from a commercial plasmid
(GenScript, OHu22944) and cloned into the multiple cloning site of a modified
pTRIPZ vector67. The correct insertion was verified by Sanger sequencing. The
PCR and sequencing primers are listed in Supplementary Table 2. A673 cells were
transduced with this lentiviral vector containing a puromycin-resistance cassette,
and a tet-responsive element for Dox-inducible expression of full-length cDNA of
SOX6 (A673/TR/cSOX6). Successfully transduced cells were selected with 0.5 µg/ml
puromycin. Overexpression of SOX6 was achieved by addition of 1 µg/ml Dox to
the culture medium.
Western blot. RDES/TR/shCtrl, RDES/TR/shSOX6_2, RDES/TR/shSOX6_3, TC-32/
TR/shCtrl, TC-32/TR/shSOX6_2, and TC-32/TR/shSOX6_3 EwS cells were treated
for 96 h with Dox to induce SOX6 knockdown. Whole cellular protein was extracted
with RIPA buffer containing 1mM Na3VO4 (Sigma-Aldrich) and protease inhibitor
cocktail (Sigma-Aldrich). Western blots were incubated with mouse monoclonal anti-
SOX6 antibody (1:1,000, sc-393314, Santa Cruz, Germany), rabbit monoclonal anti-
TXNIP antibody (1:1,000, ab188865, Abcam, UK) and mouse monoclonal anti-
GAPDH (1:800, sc-32233, Santa Cruz). The nitrocellulose membranes (GE Health-
care BioSciences, Germany) were secondary incubated with anti-mouse IgG (H+ L)
horseradish peroxidase coupled (1:3,000, W402b, Promega) and polyclonal anti-rabbit
IgG (1:5000, R1364HRP, OriGene, Germany). Proteins were detected using chemi-
luminescence HRP substrate (Merck). Densitometric protein quantifications were
carried out by ImageJ.
Proliferation assays. For proliferation assays, 2 × 105 EwS cells were seeded in
wells of 6-well plates and treated with 0.1 µg/ml Dox every 48 h for knockdown or
transiently transfected with Lipofectamine RNAiMAX (Invitrogen, USA) and the
respective sipool every 48 h for a total period of 96 h. Cell viability was determined
including the supernatant by counting the cells with Trypan-Blue (Sigma-Aldrich)
in standardized hemocytometers (C-Chip, Biochrom).
Clonogenic growth assays. For clonogenic growth assays, RDES and TC-32
harboring shRNAs against SOX6 were seeded at low density (200 cells) per well of a
12-well plate and grown for 21 days with renewal of Dox every 48 h. The colonies
were counted in three technical replicates and the colony area was measured with
the ImageJ Plugin ‘Colony area’. The clonogenicity index was calculated by mul-
tiplying the counted colonies with the corresponding colony area.
Sphere formation assays. For the analysis of anchorage-independent growth, EwS
cell lines RDES and TC-32 harboring Dox-inducible shRNAs against SOX6, were
pre-treated with Dox for 48 h before seeding, whereas the SOX6-low expressing cell
line A673 was pre-transfected with sipools against SOX6 48 h before seeding. Then,
1 × 103 cells/96-well were seeded in Costar Ultra-low attachment plates (Corning,
Germany) for 12d. To maintain the SOX6 knockdown during these 12d, 20 µl of
fresh medium with/without Dox was added every 48 h to the RDES and TC-32
cells, whereas the SOX6-low expressing cell line A673 was re-transfected every 48 h
with a sipool against SOX6. At day 12, wells were photographed and spheres larger
than 500 µm in diameter were counted. The area was measured using ImageJ. The
sphere volumes were calculated as follows: V= 4/3 × π × r3. The sphere index was
calculated by multiplying the counted colonies with the corresponding colony
volume.
3D bone model experiments. For experiments in 3D in vitro mineralized bone
models, TC-32/TR/shSOX6 EwS cells were additionally transduced with a vector
containing the tdTomato gene that was constitutively expressed. To generate 3D
in vitro bone models, human osteoblasts (2 strains, hOB, Sigma-Aldrich, USA and
hOB Promocell, Germany) at a concentration of 1.5 × 106 cells/ml were mixed with
7.5 × 104 TC-32/TR/shSOX6 EwS cells per ml and embedded in a fibrin gel. The gel
has been injected into u-shaped PMMA mask as and left to polymerize in a
humidified incubator.
For proliferation experiments in 3D in vitro bone models TC-32/TR/shSOX6
were pre-treated with Dox for 48 h before seeding in treated samples. Samples were
left in culture for 14 days with osteogenic medium (DMEM, 10% FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 1 U/ml penicillin and 1 μg/ml
streptomycin (all from ThermoFisher, USA) supplemented with 0.01 μM
dexamethasone, 10 mM β-glycerophosphate, 10 nM cholecalciferol, 150 μM L-
ascorbic acid-2-phosphate (all from Sigma-Aldrich, USA), changing medium twice
a week. For Elesclomol experiments, 7.5 × 104 TC-32/TR/shSOX6 cells were seeded
within the 3D bone model and kept in culture for 36 h in normal medium.
Afterwards, 10 nM Elesclomol was added to fresh normal medium and the 3D
bone model was cultured for further 4 days. Mineralization of constructs was
verified by staining hydroxyapatite deposits with Osteoimage® kit (Lonza,
Switzerland). TC-32 volume fraction and expression of Ki67 (staining with anti-
Ki67, ThermoFisher, USA) and cleaved caspase 3 (CC3) (staining with anti-CC3,
ThermoFisher) were quantified on confocal microscopy image stacks using Image J
plugins (Trainable Weka segmentation 3D and 3D geometric measure).
Cell cycle analysis. For cell cycle analysis, RDES and TC-32 cells harboring a Dox-
inducible shRNA against SOX6 were seeded at 4 × 105 cells per 10 cm dish and
subsequently starved for 56 h. Stimulation of the cells was performed with 10% FCS
for 20 h. Cells were fixed with ice-cold 70% ethanol, treated with 100 µg/ml RNAse
(ThermoFisher, USA) and stained with 50 µg/ml propidium iodide (Sigma
Aldrich). Analysis of the cell cycle was performed with BD Accuri C6 Cytometer
(BD Biosciences) by counting at least 1 × 105 events. An example for the gating
strategy is provided in Supplementary Fig. 7a.
Annexin V staining. For analysis of Annexin V positive cells, RDES and TC-32
cells harboring a Dox-inducible shRNA against SOX6 were seeded at 3 × 105 cells
per 10 cm dish and treated with 0.1 µg/ml Dox every 48 h for knockdown. After
96 h, cells were washed with PBS and cells were resuspended in 1 × Annexin V
buffer (BD Biosciences) with 5 µl of Annexin V and 5 µl PI solution for further 15
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minutes. Analysis of Annexin V positivity was performed with BD Accuri C6
Cytometer (BD Biosciences) by counting at least 1 × 105 events. An example for the
gating strategy is provided in Supplementary Fig. 7b.
Oxidative stress detection via DCF-DA fluorescence. For detection of oxidative
stress, EwS cells harboring a Dox-inducible shRNA against SOX6 were seeded at a
density of 5 × 104 cells per 2 ml per 6-well and either directly treated for 96 h with
Dox to induce the knockdown or treated with different reagents: 10 nM Elesclomol
for 48 h, 0.01 mM Nac for 48 h, 0.1 mM Tiron (disodium 4,5-dihydroxy-1,3-ben-
zenedisulfonate) for 48 h, 10 µM Menadione for 48 h, 1 µM DC_AC50 for 24 h or
1 µM BRD56491 for 24 h. For the knockdown of TXNIP, TC-32 cells were seeded
at a density of 7 × 104 cells/2 ml per 6-well and reversely transfected with siRNA
against TXNIP for 72 h. At the day of analysis, cells were incubated in their
medium with 2.5 µM DCF-DA (ThermoFisher) for 30 min at 37 °C. Afterwards,
cells were harvested and resuspended in PBS for flow cytometry analysis with
Accuri C6 Cytometer (BD Biosciences). An example for the gating strategy is
provided in Supplementary Fig. 7c.
Mito-ROS detection via MitoSOX Red. For detection of mitochondrial-ROS
(mito-ROS) normalized to the cellular abundance of mitochondria, EwS cells were
co-stained with MitoSOX Red and MitoTracker Green as recommended68. To this
end, EwS cells were seeded at a density of 1.5 × 104 cells per 6-well and incubated
with 200 nM MitoTracker Green in PBS for 30 min and afterwards co-stained with
5 µM MitoSOX Red for additional 15 min at 37 °C. Subsequently cells were washed
twice with PBS, harvested and resuspended in PBS for flow cytometry analysis with
an Accuri C6 Cytometer (BD Biosciences). An example for the gating strategy is
provided in Supplementary Fig. 7d. To account for variations in relative fluores-
cence of MitoSOX Red and DCF-DA across experiments, data are shown as fold
changes of the experimental groups over the respective controls that were nor-
malized to 100% in each experiment.
Gene expression and drug-response correlation. To identify drugs whose effi-
cacy correlates with SOX6 expression in EwS cells, publicly available EwS cell line
gene expression microarray data and drug-response values were downloaded from
the EBI (E-MTAB-3610) and from www.cancerrxgene.org31. All CEL-files gener-
ated on Affymetrix Human Genome U219 arrays were simultaneously normalized
using RMA60 and a custom brainarray chip description file (v20, ENTREZG)
yielding one optimized probe set for each gene61. For all drugs tested in EwS cell
lines, the Pearson correlation coefficient and its significance between SOX6
expression and IC50 values were calculated. Besides a high negative correlation
coefficient and significance level (P ≤ 0.05), low IC50 values were chosen as criteria
for selection of plausible and potentially relevant gene expression-drug-response
dependencies.
Drug-response assays and Elesclomol-treatment. For Elesclomol-treatment,
2.5 × 103 cells of RDES and TC-32 with Dox-inducible SOX6 knockdown or A673
cells with Dox-inducible SOX6 overexpression as well as MSC-52 and SAOS-2 cell
lines were seeded in wells of 96-well plates. Cells were pre-treated for 48 h with 0.1
µg/ml Dox to induce SOX6 knockdown or with 1 µg/ml Dox to overexpress SOX6,
before addition of Elesclomol (STA-4783) (Selleckchem, Germany). Different
concentrations of Elesclomol ranging from 0.1 nM to 10 µM with/without Dox or
0.1–25 µM of Menadione or 50 µM–1M DC_AC50/BRD56491 were added in a
total volume of 100 µl per technical replicate for further 72 h.
In antioxidant experiments with N-acetyl cysteine (Nac) (Sigma-Aldrich) or
Tiron (Sigma-Aldrich), cells were additionally treated with 0.01 mM Nac or 0.1
mM Tiron for 72 h. For the rescue experiments with H2O2, 2.5 × 103 cells/well were
seeded in 96-well plates and SOX6 knockdown was induced by addition of Dox.
After 48 h, cells were either treated with Elesclomol (10 nM) or vehicle, and in
addition with 30 mmol/l H2O2.
For drug-response assays in TXNIP silenced EwS cells, cells were first
transfected with specific siRNAs directed against TXNIP (10 nmol) and after 48 h,
Elesclomol was added to the culture media for 72 h. Similarly, for TXNIP rescue
experiments, SOX6-silenced EwS cells with Cumate-inducible re-expression
systems for TXINP were pre-treated with Cumate (5 µg/ml) before addition of
Elesclomol. At the day of evaluation, Resazurin (16 µg/ml; Sigma-Aldrich) was
added in order to measure cell viability. The relative IC50 concentrations were
calculated using PRISM 5 (GraphPad Software Inc., CA, USA) and normalized to
the respective controls.
In vivo experiments in mice. 3 × 106 EwS cells harboring a shRNA against SOX6
were injected in a 1:1 mix of cells suspended in PBS with Geltrex Basement
Membrane Mix (ThermoFisher) in the right flank of 10–12 weeks old NOD/Scid/
gamma (NSG) mice. Tumor diameters were measured every second day with a
caliper and tumor volume was calculated by the formula L × l2/2. When the tumors
reached an average volume of 80 mm3, mice were randomized in two groups of
which one was henceforth treated with 2 mg/ml Dox (BelaDox, Bela-pharm,
Germany) dissolved in drinking water containing 5% sucrose (Sigma-Aldrich) to
induce an in vivo knockdown (Dox (+)), whereas the other group only received 5%
sucrose (control, Dox (−)). Once tumors of control groups reached an average
volume of 1,500 mm3, all mice of the experiment were sacrificed by cervical dis-
location. Other humane endpoints were determined as follows: Ulcerated tumors,
loss of 20% body weight, constant curved or crouched body posture, bloody
diarrhea or rectal prolapse, abnormal breathing, severe dehydration, visible
abdominal distention, obese Body Condition Scores (BCS), apathy, and self-
isolation. For in vivo experiments using Elesclomol, EwS cells were subcutaneously
injected in mice as described above. When the tumors reached an average volume
of 80 mm3, mice were randomly distributed in equal groups and henceforth treated
once per day intravenously (i.v.) with 5 mg/kg Elesclomol or vehicle (DMSO),
interrupted for a two-day break on days 6 and 7 to allow mice to recover from the
i.v. injections.
For analysis of EwS growth in bone, several bone injection models have been
described for EwS69,70. In this study, EwS cells were orthotopically injected into the
proximal tibial plateau of NSG mice69. To this end, mice were first analgo-
anesthetized by i.p. injection with 0.5 mg/kg Medetomidine (Prodivet
pharmaceuticals, Belgium), 5 mg/kg Midazolam (Roche Pharma, Germany) and
0.05 mg/kg Fentanyl (Dechra Veterinary Products, Germany) (per body weight).
After disinfection of the injection site, 2 × 105 cells/20 µl were directly injected with
a fine 28 G needle (Hamilton, USA) into the right proximal tibia. Thereafter, the
initial analgo-anesthetics were antagonized with 1.2 mg/kg Naloxone (B. Braun
Melsungen AG, Germany) and 2.5 mg/kg Atipamezole (Prodivet pharmaceuticals,
Belgium) subcutaneously. For durable pain prophylaxis until the first day after
intraosseous injection, mice were subsequently treated with 0.05 mg/kg
Buprenorphine i.p. (Richter Pharma AG, Austria) (per body weight). At the first
day after injection of tumor cells, mice were randomized in two groups of which
one received henceforth 2 mg/ml Dox (BelaDox, Bela-pharm) dissolved in drinking
water containing 5% sucrose (Sigma-Aldrich) to induce the SOX6 knockdown
(Dox (+)), whereas the other group only received 5% sucrose (control, Dox (−)).
All tumor-bearing mice were sacrificed by cervical dislocation at the predefined
experimental endpoint, when 40% of control tumors exceeded a volume of 1500
mm3 for subcutaneous injection models, or in the case of the orthotopic mouse
model when the mice reached a humane endpoint as listed above or exhibited signs
of limping at the injected leg. The tumors were extracted, small piece was snap
frozen in liquid nitrogen for RNA isolation and the remaining tumor tissue was
fixed in 4%-formalin and paraffin-embedded for immunohistology. Animal
experiments were approved by the government of Upper Bavaria and conducted in
accordance with ARRIVE guidelines, recommendations of the European
Community (86/609/EEC), and United Kingdom Coordinating Committee on
Cancer Research (UKCCCR) guidelines for the welfare and use of animals in
cancer research.
Patient-derived xenograft (PDX) models. For the establishment of xenografts,
tumor specimens from EwS patients were surgically removed and cut into indi-
vidual pieces of 3–4 mm and subcutaneously transplanted into immunodeficient
NOD/SCID mice. The sex of the recipient mice was chosen accordingly to the
donor patient. PDX tumor diameters were measured every second day with a
caliper and tumor volumes were calculated by the formula L × l2/2. When the
PDXs reached an average volume of 1500 mm3 (defined endpoint), mice were
sacrificed by cervical dislocation. PDX tumors were extracted, fixed in 4% formalin
and subsequently paraffin-embedded for immunohistology. All animal experiments
were conducted in collaboration with Experimental Pharmacology and Oncology
GmbH, Berlin Buch in accordance with the UKCCCR for the welfare and use of
animals in cancer research, the German Animal Protection Law and had been
approved by local authorities (LaGeSo, Berlin, Germany).
Human samples and ethics approval. Human tissue samples were analyzed at the
Institute of Pathology of the LMU Munich (Germany) with approval of the
institutional review board. All patients/guardians provided written informed con-
sent. All analyses were approved by the ethics committee of the LMU Munich
(approval no. 18-481 UE).
Immunohistochemistry (IHC) and immunoreactivity scoring. For IHC, 4-μm
sections were cut and antigen retrieval was carried out by heat treatment with
Target Retrieval Solution (S1699, Agilent Technologies, Germany) for SOX6 and
Ki67, or Epitope Retrieval Solution pH6 (RE7113, Novocastra, Germany) for
TXNIP staining. The slides were stained with either polyclonal anti-SOX6 antibody
raised in rabbit (1:1600; HPA003908, Atlas Antibodies, Sweden) or with mono-
clonal anti-Ki67 raised in rabbit (1:200, 275R-15, Cell Marque/Sigma-Aldrich) or
with a monoclonal anti-TXNIP antibody raised in rabbit (1:250; EPR14774,
Abcam) for 60 min at RT, followed by a monoclonal secondary horseradish per-
oxidase (HRP)-coupled horse-anti-rabbit antibody (ImmPRESS Reagent Kit, MP-
7401, Vector Laboratories, Germany). AEC-Plus (K3469, Agilent Technologies) for
Ki67 and SOX6 staining or DAB+ (K3468, Agilent Technologies) for TXNIP
staining were used as chromogens. Samples were counterstained with hematoxylin
(H-3401, Vector Laboratories). For cleaved caspase 3 staining, antigen retrieval was
carried out by heat treatment with Target Retrieval Solution Citrate pH6 (S2369,
Agilent Technologies). Slides were incubated with the polyclonal cleaved caspase 3
primary antibody (rabbit, 1:100; 9661, Cell Signaling, Frankfurt am Main, Ger-
many) for 60 min at RT followed by ImmPRESS Reagent Kit. DAB+ (K3468,
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Agilent Technologies) was used as chromogen and hematoxylin for counter-
staining. All formalin-fixed and paraffin-embedded (FFPE) xenografts of the EwS
cell lines were stained with hematoxylin and eosin (H&E) to assess tissue integrity.
Assessment of mitoses, necrosis and IHC markers was carried out on at least two
sections per xenograft. Evaluation of immunoreactivity of SOX6 and TXNIP was
carried out in analogy to scoring of hormone receptor Immune Reactive Score
(IRS) ranging from 0–12. The percentage of cells with expression of the given
antigen was scored and classified in five grades (grade 0= 0–19%, grade 1=
20–39%, grade 2= 40–59%, grade 3= 60–79% and grade 4= 80−100%). In
addition, the intensity of marker immunoreactivity was determined (grade 0 =
none, grade 1 = low, grade 2 = moderate and grade 3 = strong). The product of
these two grades defined the final IRS.
Statistical analysis and software. Statistical data analysis was performed using
PRISM 5 (GraphPad Software Inc., Ca, USA) on the raw data. If not specified
otherwise in the figure legends, comparison of two groups in functional in vitro
experiments was carried out using a two-sided Mann–Whitney test. If not specified
otherwise in the figure legends, data are presented as dot plots with horizontal bars
representing means and whiskers representing the standard error of the mean
(SEM). Sample size for all in vitro experiments were chosen empirically. For in vivo
experiments, the sample size was predetermined using power calculations with β=
0.8 and α<0.05 based on preliminary data and in compliance with the 3R system
(replacement, reduction, refinement). In Kaplan–Meier analyses of event-free
survival, curves were calculated from all individual mice. Statistical differences
between the groups were assessed by a Mantel–Haenszel test.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this paper.
Data availability
The microarray data were deposited at the National Center for Biotechnology
Information (NCBI) GEO database under the accession code GSE120576. The
microarray, DNase-Seq and ChIP-Seq data referenced during the study are available in a
public repository from the GEO website (https://www.ncbi.nlm.nih.gov/geo/); accession
codes: GSE34620, GSE37371, GSE88826, GSE64686, GSM736570, and GSE61944. The
source data underlying Figs. 1a–b, 2a–c, e–f, 3a–d, f–i, 4a–k, 5a–g, 6a–h and
Supplementary Figs. 1a, 2a–c, 3a–j, 4a–c, 5a–c and 6a–c are provided as a Source Data
file. All the other data supporting the findings of this study are available within the article
and its supplementary information files and from the corresponding author upon
reasonable request.
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Custom code is available from the corresponding author upon reasonable request.
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